Genialis builds in silico models of disease biology to advance discovery & de-risk development of novel therapeutics.
#Genialis CEO @rafecooks was co-author on a Phase Ib Study of @OncXerna's Navicixizumab that demonstrated promising results for the novel bi-specific anti-angiogenic agent with minimal toxicity for patients with platinum-resistant #ovariancancer https://www.genialis.com/2022/05/17/phase-ib-study-of-navicixizumab-plus-paclitaxel-in-patients-with-platinum-resistant-ovarian-primary-peritoneal-or-fallopian-tube-cancer/ #biomarker
#Genialis is proud to announce it has passed an external CO/IEC 27001:2013 certification audit for the fifth consecutive year, further validating our commitment to securing our customers' most sensitive and valuable data. Learn more here: https://www.genialis.com/2022/05/18/genialis-renews-iso-27001-certification-for-fifth-year-running/
Today, May 12, is #InternationalNursesDay! #Genialis would like to say #ThankYou to all of the nurses worldwide who work tirelessly to ensure we all live healthy lives. #IND2022 #VoiceToLeadYou @ICNurses
Today is #NationalWomensCheckupDay! Mammograms do not prevent #breastcancer, but they do help save lives by finding breast cancer as early as possible. Check out this article highlighting everything you need to know about mammograms: https://www.breastcancer.org/screening-testing/mammograms/benefits-risks
ResponderID was named a @FastCompany "World Changing Idea!" #Clinicaltrials that stratify patients with a #biomarker are more likely to progress. This award recognizes our work to put the patient at the center of the #AIML revolution transforming #LifeScience #FCWorldChangingIdea